According to Canadian news site Financial Post, US border guards have detained 13 Canadian cannabis investors on their way to a conference in Las Vegas. One of those has been allegedly issued with a lifetime entry ban into the US which is a major cause of concern.
Now an increasing number of corporate advisors and Australian pot stocks are doing business in the US now. Biotechs developing registered drugs such as Medlab Clinical Limited (ASX: MDC) is among the majority of ASX pot stocks looking at playing in the US market. The stock price is at $0.365 as at November 22, 2018.
For Australians in the cannabis industry who are looking to travel to the USA, it’s definitely a problem says Nov Dagan from Peak. Until it’s legal on a federal level, the way they see it is there is a risk that Australians could get banned for 5-20 years. To cope with these risks, there are a number of firms that have altered travel arrangements in Canada.
To stop any TSX-listed ventures from participating at all in the US cannabis industry, in late 2017 the Toronto Stock Exchange (TSX), says New Cannabis Ventures. Of course, lawyers for those companies have worked out ways around those rules. For example, if cannabis is legalized federally there, CannTrust could give up for $US1 any royalties it would have earned in the US but has the right to buy them back.
To entice Canada’s pot stocks to head south and take up residence in New York, the NASDAQ and the NYSE are doing everything they can, which is a problem. Aphria, Aurora Cannabis, Cronos, Tilray and Canopy Growth are already there.
For the supply of terpenes to United Kingdom based, E-Quits Group, eSense-Lab Ltd. (ASX: ESE) has continued its commercialization activities by finalizing negotiations and singing of a commercial supply agreement. In the last two weeks Bod Australia (ASX: BDA) scored export licenses. The stock price is at $0.040 and $0.570 respectively as at November 22, 2018.
Zelda (ASX: ZLD) and AusCann (ASX:AC8) are trading on an over-the-counter (OTC) early stage venture market in the US, a platform that allows, without using an exchange as an intermediary, people to directly buy and sell stock from one another. The stock price is at $0.046 and $0.735 respectively as at November 22, 2018.
AusCann (ASX:AC8) group in Australia is all set to start making its pot pain pills.
To research, growing and manufacturing licenses thirteen pot stocks now have access to. Allan McCallum, chairman of Cann Group (ASX: CAN) told investors the timeline for their new Melbourne airport facility, as they’ve expanded the scale of the whole thing and made it a bit high tech, has puffed out by six months. The stock price is at $2.530 as at November 22, 2018.
CannaQIX®50 to patients in Brazil through its importation representative partner MedDepot Brazil, that Creso Pharma Limited (ASX: CPH) has commenced the importation and sale of its medicinal cannabis product. The stock price is at $0.405 as at November 22, 2018.
He said at the AGM ‘given the current wholesale price of cannabis dry flower, this new facility will generate revenues of between $160 and $200 million, with a capacity of up to 50,000 kg.’ By the end of next year, CEO Peter Crock said stage one should be ready when first cultivation can start.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.